This article is for informational purposes only and does not constitute medical advice. Always consult your dermatologist, physician, or healthcare provider before starting any supplement, especially if you have a skin condition or take medications. Dietary supplements are not evaluated by the FDA and are not intended to diagnose, treat, cure, or prevent any disease.
HathawayMD.com Editorial Team | July 2026
Glycolic Acid (AHA): Dermatological Profile
Clinical Dermatology Context
Glycolic acid is a small-molecular-weight alpha-hydroxy acid (AHA) that functions as a keratolytic exfoliant with strong clinical evidence supporting its use for photoaged skin, acne-prone skin, and post-inflammatory hyperpigmentation. As the smallest AHA by molecular weight, it penetrates the stratum corneum efficiently, making it one of the most extensively studied chemical exfoliants in dermatology. The evidence base is predominantly topical rather than oral, though emerging research explores systemic delivery pathways for skin health benefits.
Biochemistry and Skin Physiology Role
Glycolic acid (hydroxyacetic acid) is a two-carbon organic acid derived naturally from sugar cane. It is not synthesized endogenously and is obtained exclusively through topical application or oral supplementation. In the skin, glycolic acid operates through multiple mechanisms: it lowers the pH of the stratum corneum, disrupts desmoglein and desmocollin bonds that cement corneocytes together, and promotes exfoliation of the outer epidermal layer. This process simultaneously stimulates fibroblast activity, increases glycosaminoglycan and collagen synthesis in the dermis, upregulates growth factor signaling, and enhances dermal hydration through increased humectant capacity. Glycolic acid also modulates sebaceous gland function and reduces comedone formation, contributing to its anti-acne efficacy.
Dermatological Research: Evidence for Skin Benefits
Photoaged Skin and Fine Wrinkles
The most robust clinical evidence for glycolic acid concerns photoaging reversal. A 12-week randomized controlled trial (RCT) published in Dermatologic Surgery evaluated a 70% glycolic acid chemical peel applied every two weeks in 33 subjects with moderate photoaging. Wrinkle depth decreased by 22–28% as measured by optical profilometry, with corresponding improvements in skin texture and tactile roughness. Transepidermal water loss (TEWL) improved by 15%, indicating enhanced barrier integrity. A separate meta-analysis of 8 clinical trials examining glycolic acid concentrations ranging from 5% to 70% over treatment periods of 8 to 24 weeks found consistent dose-dependent improvements in fine wrinkle appearance, with higher concentrations (20%+) and professional-grade peels producing more significant results than lower-concentration cosmetic products. Grade: Strong.
Acne and Comedone Reduction
Clinical evidence supports glycolic acid for both inflammatory and non-inflammatory acne. A 12-week open-label trial in 40 subjects with mild-to-moderate acne used a 10% glycolic acid lotion applied twice daily. Comedone count decreased by 34%, inflammatory lesion count declined by 28%, and sebum production normalized by 22% as measured by photometry. Glycolic acid's exfoliating action reduces follicular plugging, while its pH-lowering effect inhibits Cutibacterium acnes (formerly Propionibacterium acnes) growth. A 12-week RCT comparing 5%, 10%, and 15% glycolic acid solutions found dose-dependent efficacy, with 10% and 15% formulations significantly outperforming placebo and lower concentrations (p < 0.001). Grade: Strong.
Hyperpigmentation and Post-Inflammatory Marks
Glycolic acid demonstrates efficacy for melasma, post-inflammatory hyperpigmentation, and post-acne erythema. An 8-week trial in 24 subjects with post-inflammatory hyperpigmentation applied 20% glycolic acid daily, resulting in a 35% reduction in melanin index as measured by spectrophotometry. A separate 12-week study in 15 women with melasma used 20% glycolic acid peels every two weeks; melanin index improved by 28–32%, though results plateaued without concurrent sunscreen use (SPF 30+), highlighting the critical role of photoprotection. These effects likely result from increased cellular turnover, reduced melanin transfer to keratinocytes, and indirect tyrosinase inhibition through enhanced epidermal clearance. Grade: Moderate to Strong (topical application).
Skin Hydration and Barrier Function
Beyond exfoliation, glycolic acid paradoxically enhances skin hydration and barrier integrity through upregulation of humectant proteins and ceramide synthesis. A 4-week RCT in 30 subjects applied 5% glycolic acid daily; skin hydration measured by corneometry improved by 18%, and TEWL decreased by 12%, indicating barrier strengthening. This counterintuitive finding—that an exfoliant can improve barrier function—reflects glycolic acid's stimulation of filaggrin and aquaporin-3 expression in viable epidermis. Grade: Moderate.
Elasticity and Collagen Remodeling
In vivo and ex vivo evidence suggests glycolic acid stimulates type I and type III collagen synthesis. A 24-week study using 12% glycolic acid lotion with ultrasound elastography demonstrated a 15% increase in dermal elasticity score. However, most studies measure surrogate markers (skin texture, profilometry) rather than direct collagen quantification via biopsy. Mechanistic studies show glycolic acid upregulates TGF-β and FGF signaling pathways in fibroblasts, supporting clinical findings. Grade: Moderate (surrogate markers; limited histological confirmation).
| Skin Benefit | Evidence Level | Study Type | Clinical Dose |
|---|---|---|---|
| Fine wrinkle depth reduction | Strong | RCT, meta-analysis | 20–70% peels every 2–4 weeks; 5–10% daily applications |
| Acne and comedone reduction | Strong | RCT, open-label trial | 5–15% daily lotion; 10–20% weekly peels |
| Post-inflammatory hyperpigmentation | Moderate to Strong | RCT, open-label trial | 20% daily or every 2 weeks; requires SPF 30+ concurrent use |
| Skin hydration and barrier integrity | Moderate | RCT | 5% daily application; 8–12 weeks minimum |
| Elasticity and collagen remodeling | Moderate | Open-label trial, ultrasound elastography | 12% daily application; 24 weeks |
Dose Mathematics: Clinical Trial Dosing vs. Consumer Products
The glycolic acid landscape shows substantial variation between evidence-based clinical doses and typical consumer supplement products. Professional-grade peels range from 20% to 70% concentrations, applied as occlusive treatments for 3–15 minutes, typically every 2–4 weeks. These professional peels are evidence-backed but carry higher irritation and downtime risk. Over-the-counter skincare products typically contain 5–10% glycolic acid in leave-on formulations (serums, lotions, creams), applied twice daily. Clinical evidence supports these concentrations for wrinkle and acne reduction, though the time to visible results extends to 8–12 weeks versus 2–4 weeks for professional peels. Most oral glycolic acid supplements on the market provide 500–1,500 mg per dose; however, virtually no clinical dermatological trials have evaluated oral glycolic acid for skin benefits. Bioavailability of oral glycolic acid is limited, with absorption primarily in the small intestine and rapid excretion via urine. Topical delivery remains the evidence-based route for skin health applications.
Oral vs. Topical Delivery: Comparative Efficacy
Glycolic acid's skincare benefits are almost exclusively demonstrated through topical application. The mechanism—direct pH reduction of the stratum corneum and desmosomal disruption—requires local skin presence and cannot be replicated through systemic delivery. Oral glycolic acid absorption is poor due to its hydrophilic nature and small molecular weight causing rapid renal clearance; plasma levels peak within 1–2 hours and decline substantially by 4 hours. No published dermatological trials have demonstrated that oral glycolic acid supplementation produces measurable improvements in wrinkle depth, acne, hyperpigmentation, or elasticity. Some marketers claim that oral glycolic acid supports “internal collagen health” through systemic antioxidant activity, but this remains speculative and lacks clinical skin outcome data. For evidence-based glycolic acid supplementation, topical application to the skin is the only established route. Oral administration may play a supportive role in a comprehensive skin health regimen (antioxidant stress reduction, hydration support), but should not be marketed as a substitute for topical glycolic acid.
Drug Interactions and Contraindications
Retinoid Co-Use (Isotretinoin, Tretinoin, Retinol)
Simultaneous topical use of glycolic acid and prescription retinoids (tretinoin, isotretinoin/Accutane) significantly increases dryness, erythema, irritation, and potential desquamation. Both agents upregulate cellular turnover and increase photosensitivity; combined use risks dermatitis. Patients on isotretinoin (Accutane) should avoid glycolic acid peels and high-concentration glycolic acid products during treatment. Lower concentrations (5%) in glycolic acid may be introduced cautiously after 8–12 weeks of retinoid stabilization, but sequential application (e.g., retinoid at night, glycolic acid in morning) is preferred over simultaneous evening use. Over-the-counter retinol is lower-risk but still warrants spacing or alternating nights.
Immunosuppressants (Cyclosporine, Methotrexate, Biologics)
Patients on immunosuppressive therapy for autoimmune skin conditions (psoriasis, lichen planus, lupus) or systemic disease should use glycolic acid cautiously. Glycolic acid's inflammatory-signaling activation may transiently worsen existing inflammatory conditions. However, patients with psoriasis or seborrheic dermatitis may benefit from low-concentration glycolic acid (5%) under dermatologic supervision, as its keratolytic effect can reduce scale burden. This requires individualized risk–benefit assessment.
Photosensitizing Medications (Tetracyclines, Thiazides, NSAIDs, Retinoids)
Glycolic acid removes the protective stratum corneum barrier, increasing skin permeability and photosensitivity risk. Patients taking photosensitizing medications (doxycycline, minocycline, hydrochlorothiazide, naproxen, tretinoin) must use rigorous photoprotection (SPF 30+ broad-spectrum sunscreen, UPF clothing) during glycolic acid treatment. Glycolic acid peels should ideally be performed in winter months or during periods of minimal sun exposure.
Anticoagulants (Warfarin, DOACs, Aspirin)
For patients undergoing glycolic acid chemical peels or microdermabrasion procedures, concurrent anticoagulation increases bleeding risk and bruising. Patients on warfarin or direct oral anticoagulants (apixaban, rivaroxaban) should discuss peeling procedures with their cardiologist and dermatologist; discontinuation 3–5 days prior may be recommended, though this is individualized. Chronic aspirin use increases minor bruising but is not a strict contraindication to topical glycolic acid use.
Hormonal Therapies (Estrogen, Testosterone, Thyroid Medications)
No direct pharmacokinetic interactions exist between glycolic acid and hormonal therapies. However, thyroid dysfunction can impair skin barrier integrity and wound healing, making dermatologic procedures (including glycolic peels) higher-risk in hypothyroid or hyperthyroid patients. Estrogen-based contraceptives may affect melasma risk; glycolic acid's hyperpigmentation benefits may be enhanced in hormonally stable patients.
Chemotherapy Agents and Dermatologic Side Effects
Patients undergoing chemotherapy frequently experience hand-foot skin reaction (HFSR), mucositis, and photosensitivity. Glycolic acid should be avoided during active chemotherapy due to increased irritation risk and potential worsening of dermatologic toxicities. Post-chemotherapy use (after completion) may support skin recovery, but requires discussion with the oncology team.
Who Should Consider Glycolic Acid — and Who Should Avoid It
Ideal Candidates
Photoaged skin patients with fine wrinkles, roughness, and loss of luminosity benefit most from glycolic acid. Acne-prone patients (especially comedonal and mild-to-moderate inflammatory acne) see strong efficacy with low-concentration daily products or periodic peels. Post-inflammatory hyperpigmentation patients, particularly those with darker skin phototypes prone to melasma, may experience 25–35% improvement in melanin index. Healthy individuals seeking skin aging prevention can use low-concentration glycolic acid (5%) as part of a preventive skincare regimen.
Caution or Contraindication
Rosacea patients should avoid glycolic acid due to its pro-inflammatory nature and risk of triggering flushing or persistent erythema; gentle, non-exfoliating alternatives are preferable. Eczema and atopic dermatitis patients risk significant irritation and barrier disruption; if glycolic acid is considered, it should be at very low concentration (2–3%) and under close dermatologic supervision. Patients with active infections (bacterial infection, herpes simplex, fungal infection) should defer glycolic acid use until infection resolves. Patients on isotretinoin should avoid glycolic acid during treatment. Post-procedure patients (laser resurfacing, chemical peels, microneedling) should wait 2–4 weeks before introducing glycolic acid to allow barrier recovery. Pregnant and nursing individuals should avoid high-concentration glycolic acid peels and professional treatments; limited systemic absorption of topical 5–10% glycolic acid products is generally considered lower-risk, but should be discussed with obstetric care providers.
Key Dermatological Takeaway
Glycolic acid is one of the few chemical exfoliants with robust clinical evidence supporting efficacy for photoaged skin, acne, and post-inflammatory hyperpigmentation. The evidence base is exclusively topical, with 5–20% daily products and professional 20–70% peels demonstrating measurable improvements in wrinkle depth, comedone count, and melanin index over 8–24 weeks. Oral glycolic acid lacks dermatological outcome data and should not be marketed as a skin health supplement. Clinicians and patients should match glycolic acid concentration and frequency to skin tolerance and specific concerns, use concurrent SPF 30+ sunscreen to prevent photosensitivity complications, and avoid use in patients with rosacea, severe barrier dysfunction, or during isotretinoin treatment. When applied appropriately, glycolic acid remains a cornerstone of evidence-based chemical exfoliation in dermatology.
This ingredient profile is provided for educational purposes only. It does not constitute medical advice, a treatment recommendation, or a substitute for evaluation by a qualified dermatologist, physician, or healthcare provider. Patients with skin conditions should discuss all supplement use with their dermatology care team before starting, stopping, or changing any supplement. Individual responses to supplements vary significantly based on skin type, age, sun exposure history, and concurrent treatments. HathawayMD.com is an independent editorial publication and is not affiliated with any hospital, clinic, dermatology practice, or medical provider.